OREGOVOMAB WITH OR WITHOUT CYCLOPHOSPHAMIDE IN TREATING PATIENTS WITH STAGE III OR STAGE IV OVARIAN EPITHELIAL CANCER, FALLOPIAN TUBE CANCER, OR PRIMARY PERITONEAL CANCER THAT RESPONDED TO SECOND-LINE CHEMOTHERAPY: